ClinicalTrials.Veeva

Menu

Cough Management Wellness App for Refractory or Unexplained Chronic Cough

H

Hyfe

Status

Enrolling

Conditions

Unexplained Chronic Cough
Cough Hypersensitivity
Refractory Chronic Cough

Treatments

Behavioral: Cough Management
Device: CoughMonitor Suite

Study type

Interventional

Funder types

Other

Identifiers

NCT07070895
CPCoMg-001

Details and patient eligibility

About

The goal of this single-cohort clinical trial is to learn whether a smartphone-based Cough Management (CM) program can reduce cough frequency and burden in adults (21-80 years) who have refractory or unexplained chronic cough. 

The main questions it aims to answer are:

  • Does four weeks of using the CM feature in the CoughPro app lower objective cough rate (coughs per hour) compared with each participant's one-week baseline? 
  • Does the program also lessen cough intensity (bout metrics) and improve patient-reported quality-of-life scores on the Leicester Cough Questionnaire and PGI-S?

Participants will:

  • Wear a Hyfe CoughMonitor smartwatch continuously for 6 weeks (1-week baseline, 4-week intervention, 1-week follow-up), charging it nightly. 
  • Complete science-based in-app CM lessons based on behavioral cough-suppression therapy and practice the techniques during the 4-week intervention.
  • Fill out online questionnaires (LCQ and PGI-S) at baseline and at the end of Week 4.
  • Join a brief exit interview, then return the smartwatch and receive a compensation voucher.

Enrollment

20 estimated patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 21 or older.
  • Currently suffering from a cough that started at least 8 weeks ago that is largely unproductive (i.e., at least 50% of the time the cough produces zero mucus that needs to be spit out or swallowed).
  • Normal chest X-ray or chest CT scan at some point that was prescribed specifically for their cough.
  • At least one physician visit for cough with standard-of-care therapy but inadequate symptom relief.
  • Stability of treatment: willing to avoid new cough treatments during study or report changes if they occur.
  • Ability to comply: willing/able to wear the watch daily for the required duration of study and to complete all required questionnaires.
  • Informed consent: understanding of the study procedures and agreement to comply with protocol.

Exclusion criteria

  • Recent upper respiratory infection (past 4 weeks).
  • History of hemoptysis (coughing up blood) since onset of the current cough.
  • Current smoker (incl. vaping) of any substance.
  • ≥10 consecutive pack-years smoking history within <10 years prior to screening.
  • Diagnosed with a chronic lung condition (COPD, emphysema, lung cancer, IPF, chronic bronchitis, asthma). Note: Suspected asthma without confirmed diagnosis or benefit from asthma therapy is not an exclusion.
  • Current or past head/neck cancer.
  • Difficulty swallowing.
  • On ACE inhibitors, such as Benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik)
  • Prior treatment for cough by a speech-language pathologist.
  • Living with another individual with a frequent cough that would interfere with monitoring.
  • Participation in any cough intervention study within 30 days or 5 half-lives of the intervention.
  • Major scheduled surgery during the study period.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Cough Management
Experimental group
Description:
CoughPro wellness application includes a Cough Management (CM) component, which delivers short, structured behavioral lessons (based on BCST) designed to help users recognize their urge to cough and apply cough suppression strategies in real-world settings. The Cough Management wellness feature is the key area of investigation in this study.
Treatment:
Device: CoughMonitor Suite
Behavioral: Cough Management

Trial contacts and locations

1

Loading...

Central trial contact

Laurie Slovarp, PhD, CCC-SLP

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems